REVIEW ARTICLE

You have free access to this content

One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions

  1. M. Calderón1,*,
  2. V. Cardona2,
  3. P. Demoly3,
  4. on behalf of the EAACI 100 Years of Immunotherapy Experts Panel†

Article first published online: 6 FEB 2012

DOI: 10.1111/j.1398-9995.2012.02785.x

Issue

Allergy

Allergy

Volume 67, Issue 4, pages 462–476, April 2012

Additional Information

How to Cite

Author Information

  1. 1

    Imperial College London, National Heart and Lung Institute, London, UK

  2. 2

    University Hospital of Vall d'Hebron, Barcelona, Spain

  3. 3

    University Hospital of Montpellier, Montpellier, France

  1. †

    EAACI Experts Panel members: Giovanni Passalacqua, Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, Genoa, Italy; Jörg Kleine-Tebbe, Allergy & Asthma Center Westend, Berlin, Germany; Erkka Valovirta, Suomen Terveystalo Allergy Clinic, Turku, Finland; Stephen R Durham, Imperial College London, National Heart and Lung Institute, London, UK; Ronald Dahl, Aarhus University, Denmark; Hans-Jorgen Malling, Allergy Unit, University Hospital, Copenhagen, Denmark; Antony Frew, University of Southampton; Montserrat Fernandez-Rivas, Hospital Clinico San Carlos, IdISSC, Madrid, Spain; Rudolf Valenta, Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Austria; Ulrich Wahn, Charité University of Medicine, Berlin, Germany; Albrecht Bufe, Ruhr University, Bochum, Germany.

*Correspondence
Moisés Calderón, Imperial College London, National Heart and Lung Institute, London, UK.
Tel.: +44 20 73518024
Fax: +44 20 73497780
E-mail: m.calderon@imperial.ac.uk

  1. †

    EAACI Experts Panel members: Giovanni Passalacqua, Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, Genoa, Italy; Jörg Kleine-Tebbe, Allergy & Asthma Center Westend, Berlin, Germany; Erkka Valovirta, Suomen Terveystalo Allergy Clinic, Turku, Finland; Stephen R Durham, Imperial College London, National Heart and Lung Institute, London, UK; Ronald Dahl, Aarhus University, Denmark; Hans-Jorgen Malling, Allergy Unit, University Hospital, Copenhagen, Denmark; Antony Frew, University of Southampton; Montserrat Fernandez-Rivas, Hospital Clinico San Carlos, IdISSC, Madrid, Spain; Rudolf Valenta, Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Austria; Ulrich Wahn, Charité University of Medicine, Berlin, Germany; Albrecht Bufe, Ruhr University, Bochum, Germany.

  2. Edited by: Thomas Bieber

Publication History

  1. Issue published online: 13 MAR 2012
  2. Article first published online: 6 FEB 2012
  3. Manuscript Accepted: 19 DEC 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (259K)

References

  • 1
    Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases; EMEA/CHMP/EWP/18504/2006, 2008.
  • 2
    Committee for Medicinal Products for Human Use (CHMP). Guideline on allergen products. Production and quality issues; CPMP/EMEA/BWP/304831/2007, 2008.
  • 3
    van Ree R. The CREATE project: a new beginning of allergen standardization based on mass units of major allergens. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2003;94:70–73. discussion 74–75.
  • 4
    van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008;63:310–326.
    Direct Link:
  • 5
    Neske F, Schorner C, Buchheit KH, Costanzo A, Hanschmann KM, Himly M et al. BSP090–the follow-up to CREATE. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2009;96:12–19. discussion 19–20.
  • 6
    Calderon MA, Larenas D, Kleine-Tebbe J, Jacobsen L, Passalacqua G, Eng PA et al. European Academy of Allergy and Clinical Immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’. Allergy 2011;66:1345–1369.
    Direct Link:
  • 7
    Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009;64:669–677.
  • 8
    Malling HJ. Immunotherapy in Europe. Clin Exp Allergy 1994;24:515–521.
    Direct Link:
  • 9
    Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:734–737.
  • 10
    Hejjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992;89:925–933.
  • 11
    Malling HJ, Weeke B. Immunotherapy. EAACI Position Paper. Allergy 1993;14(Suppl 48):9–35.
    Direct Link:
  • 12
    Pfaar O, Leitzbach S, Hormann K, Klimek L. Cluster protocols in SCIT: enough evidence for practical use? Curr Opin Allergy Clin Immunol 2010;10:188–193.
  • 13
    Mauro M, Russello M, Alesina R, Sillano V, Alessandrini A, Dama A et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol 2006;38:31–34.
  • 14
    Lombardi C, Incorvaia C, Braga M, Senna G, Canonica GW, Passalacqua G. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 2009;64:849–854.
    Direct Link:
  • 15
    Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82):1–20.
    Direct Link:
  • 16
    Tabar AI, Arroabarren E, Echechipia S, Garcia BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011;127:57–63.
  • 17
    Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131–138 e1–7.
  • 18
    Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559–566.
  • 19
    Didier A, Horak F, Worm M, Melac M, de Beaumont O, Montagut A et al. Long-term clinical efficacy of a 5-grass pollen sublingual immunotherapy tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Presented at the 30th Congress of the European Academy of Allergy and Clinical Immunology, Istanbul, Turkey 11–15 June 2011.
  • 20
    Baatenburg de Jong A, Dikkeschei LD, Brand PL. Sensitization patterns to food and inhalant allergens in childhood: a comparison of non-sensitized, monosensitized, and polysensitized children. Pediatr Allergy Immunol 2011;22:166–171.
    Direct Link:
  • 21
    Bousquet PJ, Castelli C, Daures JP, Heinrich J, Hooper R, Sunyer J et al. Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I). Ann Epidemiol 2010;20:797–803.
  • 22
    Didier A, Chartier A, Demonet G. Specific sublingual immunotherapy: for which profiles of patients in practice? Midterm analysis of ODISSEE (observatory of the indication and management of respiratory allergies [rhinitis and / or conjunctivitis and / or allergic asthma] by specific sublingual immunotherapy). Revue française d'allergologie 2010;50:426–433.
  • 23
    Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012; in press.
  • 24
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319–325.
  • 25
    Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009;39:387–393.
    Direct Link:
  • 26
    Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009;123:763–769.
  • 27
    Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997;99(6 Pt 1):744–751.
  • 28
    Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992;90:256–262.
  • 29
    Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010;126:83–91 e1.
  • 30
    Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009;124:286–291. 291 e1–6.
  • 31
    Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009;124:292–300. 300 e1–97.
  • 32
    Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 2008;121:343–347.
  • 33
    Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy 2004;59:980–987.
    Direct Link:
  • 34
    Meglio P, Giampietro PG, Gianni S, Galli E. Oral desensitization in children with immunoglobulin E-mediated cow's milk allergy–follow-up at 4 yr and 8 months. Pediatr Allergy Immunol 2008;19:412–419.
    Direct Link:
  • 35
    Morisset M, Moneret-Vautrin DA, Guenard L, Cuny JM, Frentz P, Hatahet R et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol 2007;39:12–19.
  • 36
    Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol 2010;105:376–381.
  • 37
    Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, De Pasquale T et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 2003;17:459–465.
    Direct Link:
  • 38
    Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 2008;122:1154–1160.
  • 39
    Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 2007;62:1261–1269.
    Direct Link:
  • 40
    Zapatero L, Alonso E, Fuentes V, Martinez MI. Oral desensitization in children with cow's milk allergy. J Investig Allergol Clin Immunol 2008;18:389–396.
  • 41
    Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000;55:69–73.
    Direct Link:
  • 42
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–475.
  • 43
    Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61:198–201.
    Direct Link:
  • 44
    Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943–948.
    Direct Link:
  • 45
    Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450–453.
  • 46
    Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 2007;17:85–91.
  • 47
    Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392–1397.
    Direct Link:
  • 48
    Purello-D'Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31:1295–1302.
    Direct Link:
  • 49
    Reha CM, Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 2007;35:44–51.
  • 50
    Tella R, Bartra J, San Miguel M, Olona M, Bosque M, Gaig P et al. Effects of specific immunotherapy on the development of new sensitisations in monosensitised patients. Allergol Immunopathol (Madr) 2003;31:221–225.
  • 51
    Crimi N, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, Vancheri C et al. A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms. Ann Ital Med Int 2004;19:98–108.
  • 52
    Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C, Kalayci O. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 2006;17:396–407.
    Direct Link:
  • 53
    Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881–891.
  • 54
    Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005;6:153.
  • 55
    Polosa R, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, Vancheri C et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004;59:1224–1228.
    Direct Link:
  • 56
    Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101:206–211.
  • 57
    Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study. http://clinicaltrials.gov/ct2/show/NCT00346398?term=Promoting+Tolerance+to+Common+Allergens+in+High-Risk+Children%3A+Global+Prevention+of+Asthma+in+Children+%28GPAC%29+Study&rank=1.
  • 58
    Grazax Asthma Prevention (GAP) Study. http://clinicaltrials.gov/ct2/show/NCT01061203?term=Grazax+Asthma+Prevention+%28GAP%29+trial&rank=1.
  • 59
    Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990;85:473–479.
  • 60
    Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann Allergy Asthma Immunol 2007;98:416–426.
  • 61
    European Declaration on Immunotherapy: Combating Allergy Beyond Symptoms. http://eaaci.net/eaacimedia/1663-eaacipresents-the-european-declaration-onallergen-immunotherapy.
  • 62
    Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol 2008;100:137–145.
  • 63
    Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005;116:1073–1079.
  • 64
    Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE, Gonzalez-Mancebo E et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 2009;64:876–883.
    Direct Link:
  • 65
    Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011;127:640–646 e1.
  • 66
    Sjovall P, Christensen OB, Moller H. Oral hyposensitization in nickel allergy. J Am Acad Dermatol 1987;17(5 Pt 1):774–778.
  • 67
    Tammaro A, De Marco G, Persechino S, Narcisi A, Camplone G. Allergy to nickel: first results on patients administered with an oral hyposensitization therapy. Int J Immunopathol Pharmacol 2009;22:837–840.
  • 68
    Schiavino D, Nucera E, Alonzi C, Buonomo A, Pollastrini E, Roncallo C et al. A clinical trial of oral hyposensitization in systemic allergy to nickel. Int J Immunopathol Pharmacol 2006;19:593–600.
  • 69
    Bagot M, Terki N, Bacha S, Moyse D, Suck C, Revuz J. [Per os desensitization in nickel contact eczema: a double-blind placebo-controlled clinico-biological study]. Ann Dermatol Venereol 1999;126:502–504.
  • 70
    Troost RJ, Kozel MM, van Helden-Meeuwsen CG, van Joost T, Mulder PG, Benner R et al. Hyposensitization in nickel allergic contact dermatitis: clinical and immunologic monitoring. J Am Acad Dermatol 1995;32:576–583.
  • 71
    Morris DL. Intradermal testing and sublingual desensitization for nickel. Cutis 1998;61:129–132.
  • 72
    Panzani RC, Schiavino D, Nucera E, Pellegrino S, Fais G, Schinco G et al. Oral hyposensitization to nickel allergy: preliminary clinical results. Int Arch Allergy Immunol 1995;107:251–254.
  • 73
    Caliskaner Z, Ozturk S, Turan M, Karaayvaz M. Skin test positivity to aeroallergens in the patients with chronic urticaria without allergic respiratory disease. J Investig Allergol Clin Immunol 2004;14:50–54.
  • 74
    Kulthanan K, Wachirakaphan C. Prevalence and clinical characteristics of chronic urticaria and positive skin prick testing to mites. Acta Derm Venereol 2008;88:584–588.
  • 75
    Mahesh PA, Kushalappa PA, Holla AD, Vedanthan PK. House dust mite sensitivity is a factor in chronic urticaria. Indian J Dermatol Venereol Leprol 2005;71:99–101.
  • 76
    Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am J Clin Dermatol 2004;5:281–294.
  • 77
    Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:1292–1298.
  • 78
    Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007;120:164–170.
  • 79
    Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 2008;122:44–48.
  • 80
    Patriarca G, Nucera E, Roncallo C, Aruanno A, Lombardo C, Decinti M et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol 2008;21:669–677.
  • 81
    Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:537–543.
  • 82
    Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908–17912.
  • 83
    Senti G, Graf N, Haug S, Ruedi N, von Moos S, Sonderegger T et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997–1002.
  • 84
    Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010;65:410–411.
    Direct Link:
  • 85
    Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154(6 Pt 1):1623–1628.
  • 86
    Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996;8:1937–1945.
  • 87
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608–613.
  • 88
    Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951–960.
  • 89
    Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004;101(Suppl 2):14677–14682.
  • 90
    Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008;38:1514–1525.
    Direct Link:
  • 91
    Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008;145:193–206.
  • 92
    Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010;28:211–241.
  • 93
    Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011;127:860–864.
  • 94
    Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445–1455.
  • 95
    Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470–1476.
  • 96
    Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009;206:1941–1955.
  • 97
    Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010;40:385–397.
    Direct Link:
  • 98
    Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009;182:6298–6306.
  • 99
    Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011;127:1562–1570 e6.
  • 100
    Slater JE, Paupore E, Zhang YT, Colberg-Poley AM. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol 1998;102:469–475.
  • 101
    Hochreiter R, Stepanoska T, Ferreira F, Valenta R, Vrtala S, Thalhamer J et al. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur J Immunol 2003;33:1667–1676.
    Direct Link:
  • 102
    Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostbock S et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009;124:1070–1077 e1–11.
View Full Article (HTML) Get PDF (259K)